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Our study describes the incidence and risk factors for undiagnosed diabetes in elderly cancer patients. Using Surveillance,
Epidemiology, and EndResults-Medicare data, we followed patients with breast, colorectal, lung, or prostate cancer from 24months
before to 3 months after cancer diagnosis. Medicare claims were used to exclude patients with diabetes 24 to 4 months before
cancer (look-back period), identify those with diabetes undiagnosed until cancer, and construct indicators of preventive services,
physician contact, and comorbidity during the look-back period. Logistic regression analyses were performed to identify factors
associated with undiagnosed diabetes. Overall, 2,678 patients had diabetes undiagnosed until cancer. Rates were the highest in
patients with both advanced-stage cancer and low prior primary care/medical specialist contact (breast 8.2%, colorectal 5.9%, lung
4.4%). Nonwhite race/ethnicity, living in a census tract with a higher percent of the population in poverty and a lower percent
college educated, lower prior preventive services use, and lack of primary care and/or medical specialist care prior to cancer all
were associated with higher (𝑃 ≤ 0.05) adjusted odds of undiagnosed diabetes. Undiagnosed diabetes is relatively common in
selected subgroups of cancer patients, including those already at high risk of poor outcomes due to advanced cancer stage.
1. Introduction
Diabetes and the metabolic derangements typical of diabetes
are associated with poor prognosis in cancer [1–11]. In per-
haps the most comprehensive study to date; Barone and col-
leagues [2] performed a systematic review and meta-analysis
of the literature and found that preexisting diabetes was asso-
ciated with statistically significant increases of 41% for all-
cause mortality, across multiple tumor types, and 76%, 61%,
and 32% in endometrial, breast, and colorectal cancer, respec-
tively. Poor prognosis may be influenced through biological
mechanisms related to hyperglycemia, hyperinsulinemia, and
inflammation, which result in tumor cell proliferation and
metastases [3–5, 12]. Other factors include less aggressive
cancer treatment due to diabetes-related comorbidity [13],
poorer response to cancer treatment [7, 11], presentation
with later-stage cancer due to suboptimal cancer screening
practices and other preventive health-seeking behavior [14],
and that diagnosis of cancer may distract both the patient
and the health care team from appropriate management of
glycemia, blood pressure, and lipids [2].
Factors thought to play a role in observed associations
between preexisting diabetes andmortality [2] could be exac-
erbated in undiagnosed diabetes, but evidence supporting
this hypothesis is scarce. Data from the Second National
Health and Nutrition Examination Survey (NHANES) do
suggest that cancer mortality in patients with undiagnosed
diabetes may be higher than in those with previously diag-
nosed diabetes, where undiagnosed diabetes was identified
by oral glucose tolerance testing [9]. However, this study
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was conducted in the general population making the risk of
cancer mortality a function of both the risk of developing
cancer and the subsequent risk of death due to cancer. Also,
the two diabetes groups were not compared directly, and
differences in mortality compared to a reference group with
normal glucose tolerance, while suggestive of an adverse
impact, failed to reach statistical significance [9].
Data on the incidence of and risk factors for undiagnosed
diabetes in cancer also are scarce. While a recent paper
reports that detection ofmany chronic conditions—including
diabetes—increases around the time of breast cancer diagno-
sis [15], risk factors for the detection of these conditions were
not examined in detail. Several studies have examined factors
associated with cancer stage at diagnosis, an important pre-
dictor of cancer mortality, focusing on demographic and
socioeconomic characteristics and patterns of prior health
system contact [16–19]. These show that more contact with a
primary care physician and/or medical specialist [16], greater
use of general preventive and cancer screening services [17],
and more contact with the health care system as measured by
level of comorbidity ascertained throughmedical claims [18],
all are associated with earlier-stage cancer at diagnosis.
In this study, we sought to describe the incidence and
risk factors for diabetes that is undiagnosed until cancer. We
elected to focus on prior health system contact, comorbidity,
race, and socioeconomic status as risk factors since there is
evidence that all of these are associated with cancer stage
at diagnosis [16–19], which is another important prognostic
factor for cancer outcomes.
2. Methods
2.1. Data Source. The source of data for this study was the
National Cancer Institute’s (NCI) Surveillance, Epidemiol-
ogy, and End Results (SEER) cancer registry linked to Medi-
care claims [20]. Presently, SEER contains cancer incidence
and survival data from 17 population-based cancer registries
throughout the United States covering approximately 28% of
the population [21]. In SEER-Medicare, cancer registry data
are linked toMedicare enrollment and claims data, which are
available for 93% of those aged ≥65 years in the SEER registry
[22].
2.2. Inclusion and Exclusion Criteria. Patients meeting all of
the following criteria were included: they were diagnosed
with breast, colorectal, lung, or prostate cancer, the four most
common types in the elderly [23], between January 1, 1999,
and December 31, 2002. This was their first and only cancer
diagnosed, and they had at least 24 months of Medicare Part
A (hospital) and Part B (outpatient) fee-for-service coverage
prior to the diagnosis of cancer. Patients were excluded for
the following reasons: male breast cancer, cancer diagnosis
made by death certificate or autopsy, death within the first
month following diagnosis, missing or unknown cancer stage
at diagnosis, or in situ lung or prostate cancer (due to small
numbers of patients).
Patients with preexisting diabetes diagnosed between 24
and 4months (inclusive) before cancer initially were included
in the study to calculate the proportion of all diabetes cases
undiagnosed until cancer (i.e., using a denominator of pre-
existing plus undiagnosed until cancer). However, patients
with preexisting diabetes were then excluded from all the
analyses of risk factors for undiagnosed diabetes. Diabetes
was defined as the presence of one of the following Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification diagnosis codes in one inpatientMedicare claim
or in two outpatient claims at least 30 days apart: 250.xx
for diabetes and complications, 357.2x for polyneuropathy
in diabetes, 362.0x for diabetic retinopathy, and 366.41 for
diabetic cataract [24]. Laboratory claims were excluded to
reduce the likelihood of misclassifying those patients only
undergoing diagnostic evaluation for suspected diabetes as
actual diabetes cases.
2.3. Observation Period. Patients were followed from 24
months prior to the diagnosis of cancer until 3 months after
diagnosis (overall follow-up: 27 months). The observation
period was divided into two consecutive periods: 24 to 4
months prior to cancer diagnosis (the 21-month look-back
period) and 3 months prior to 3 months after diagnosis or
until death, whichever came first (the 6-month incidence
period). The first day of the SEER month of diagnosis was
assigned as the day of diagnosis. The look-back period was
used to identify preexisting (prevalent) diabetes and to con-
struct measures of prior health system contact.The incidence
period was used to identify previously undiagnosed diabetes.
2.4. Definition of Undiagnosed Diabetes. Diabetes that was
not reported in the claims until the time around cancer diag-
nosis was considered to be “undiagnosed diabetes.” It was
defined as having a first diagnosis of diabetes between 3
months before and 3 months after cancer diagnosis. The
same claims-based algorithm [24] used to identify and subse-
quently exclude patients with preexisting diabetes during the
look-back period (24 to 4 months before cancer diagnosis)
also was used to identify undiagnosed diabetes.
2.5. Patients and Variables. Patients were described accord-
ing to their demographic, clinical, and socioeconomic char-
acteristics. Requiring eligible patients to have at least two
years of Medicare enrollment prior to diagnosis meant that
the minimum age in the cohort was 67 years. Race/ethnicity
was defined using the SEER recoded race variable [25]. Stage
at cancer diagnosis was based on the SEER-modified Amer-
ican Joint Committee on Cancer (AJCC) stage variable [25].
In SEER, socioeconomic information, including measures of
poverty and education, is reported at the census tract level.
We constructed two measures of prior health system
contact during the look-back period, based on literature
describing associations between prior health system contact
and stage at cancer diagnosis [16, 17]. First, we constructed
a physician contact index that classified patients according
to the types of ambulatory care visits they received during
the look-back period [16]. We searched Medicare claims
for Healthcare Common Procedure Coding System codes
indicating physician outpatient visits and used the associated
physician specialty code to classify each visit as primary care
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physician, medical specialist, or other specialist. Other spe-
cialists included general surgeons, ophthalmologists, ortho-
pedic surgeons, and other surgical specialists [16]. Patients
were then classified as having had (A) primary care physician
but no medical specialist (with or without other specialist)
visits, (B) medical specialist but with no primary care physi-
cian (with orwithout other specialist) visits, (C) both primary
care physician andmedical specialist visit, (D) other specialist
but no primary care physician or medical specialist visits, or
(E) no prior visits.
Second, we constructed an index of preventive services
based on the one developed by Gornick et al. [17], consisting
of mammography, screening for colorectal cancer, prostate-
specific antigen test, Papanicolaou test, screening for glau-
coma, influenza immunization, and pneumonia immuniza-
tion. The presence of one or more claims for each type of
service was coded as “1” for that service, and individual scores
were combined in an index consisting of 0, 1, or ≥2.
Comorbidity is a predictor of breast cancer stage at diag-
nosis [18], and when comorbidity is identified from medical
claims, it can also be considered an indirect indicator of
increased health system contact. To account for this facet
of health system contact, we calculated an NCI comorbidity
index score for each patient [22–32].
2.6. Analyses. We calculated the proportion of all diabetes
patients diagnosed during the entire 27-month observation
period who were diagnosed during the 6-month incidence
period. We then excluded those with preexisting diabetes
from the remainder of the analyses. We performed four
multivariate logistic regression analyses, one for each type of
cancer, to examine race/ethnicity, socioeconomic factors, and
patterns of prior health system contact associated with
undiagnosed diabetes—all stratified by type of cancer. All
models included age, gender (colorectal and lung only),
race/ethnicity, year of diagnosis, education, poverty, and
geographic area. All three measures of prior health system
contact (physician contact index, index of preventive services,
and NCI Comorbidity Index) were included in each of the
four models. However, the three measures of prior health
system contact also were assessed in separate models to
evaluate the levels of multicollinearity among them.
3. Results
Initially, 184,336 patients with breast, colorectal, lung, and
prostate cancer were considered for inclusion in the study. Of
these, 11,426 (6.2%) were excluded due to missing/unknown
cancer stage (all cancer types) or in situ stage (lung and
prostate cancer only, as stated in Section 2). Of the remaining
172,910, an additional 18,218 (10.5%) were excluded prior to
the analysis of risk factors for undiagnosed diabetes because
they had preexisting diabetes diagnosed during the look-back
period: breast 3,850/40,062 (9.6%), colorectal 6,029/39,034
(15.4%), lung 4,861/40,622 (12.0%), and prostate 3,478/53,182
(6.5%).Therefore, 154,692met all the inclusion and exclusion
criteria for the analysis of risk factors associated with undi-
agnosed diabetes (Table 1). Overall, the mean age was 76.3
years: 84.7% were non-Hispanic white, 31.6% came from a
census tract with >12% poverty, and 56.0% were from a large
metropolitan area.
Among the measures of prior health system contact,
65.3% had an NCI comorbidity index score equal to 0, 78.1%
had at least one preventive service during the look-back
period, and 56.5% had visits to both a primary care physician
and a medical specialist (Table 2). This differed by cancer
type as 69.5% and 69.0% of breast cancer and prostate cancer
patients, respectively, had NCI comorbidity index scores of 0
compared to 53.9%of lung cancer patients. Breast (19.2%) and
prostate (19.6%) cancer patients were more likely to have had
no preventative service visits compared to colorectal (25.2%)
or lung (24.8%) cancer patients. Women with breast cancer
(60.4%) were more likely to have visited both a primary care
physician and medical specialist than were other patients in
this study (53.3% to 57.2%).
Overall, 2,678 had undiagnosed diabetes (Table 3). When
viewed over the entire study period (the incidence and
the prevalence look-back periods combined), undiagnosed
diabetes accounted for 12.8% (2,678/20,896) of all the diabetes
cases: 8.8% of all diabetes in breast, 13.0% of all diabetes in
colorectal, 16.8% of all diabetes in lung, and 10.8% of all
diabetes in prostate cancer (not shown in the tables). In
general, the incidence of undiagnosed diabetes in the 6-
month period around the cancer diagnosis was similar across
age groups butwas higher in those of nonwhite race/ethnicity,
those diagnosed with advanced stage cancer, those living
in a census tract with a lower proportion college educated,
and those living in a census tract with more poverty. The
incidence of undiagnosed diabeteswas inversely related to the
number of preventive services (Figure 1). It was also lower in
patients who had visits to a primary care physician and/or a
medical specialist. These associations were consistent across
the four types of cancer. Rates were highest among those with
no outpatient physician care during the look-back period
(2.2% in prostate, 5.5% in colorectal, 4.8% lung, and 3.3%
breast cancer).
In multivariate analyses that included all three measures
of prior health system contact in the samemodel, the adjusted
odds of undiagnosed diabetes were statistically significantly
lower for those with 1 or ≥2 preventive services (compared
to none) in breast, colorectal, and prostate (≥2 only) but not
in colorectal and lung cancer (Table 4). The adjusted odds of
undiagnosed diabetes also were lower for those with primary
care and/or medical specialist care prior to cancer.
In general, nonwhite race/ethnicity was associated with
increased adjusted odds of undiagnosed diabetes, as was
living in a census tract with a lower percent college educated
and a higher percent in poverty (Table 4). Overall, effect sizes
for measures of prior health system contact were larger in
models that included only one measure per model (Table 5).
4. Conclusions
In this study, we described the epidemiology of undiagnosed
diabetes in a large cohort of elderly cancer patients in the
United States. Our findings show that undiagnosed diabetes
accounted for almost 13% of all diabetes cases identified
in an older cohort of patients diagnosed with cancer. This
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Table 1: Patient characteristics.
Overall Type of cancer
Breast Colorectal Lung Prostate
𝑁 % (SD) 𝑛 % (SD) 𝑛 % (SD) 𝑛 % (SD) 𝑛 % (SD)
154,692 100 36,212 23.4 33,005 21.3 35,761 23.1 49,714 32.1
Age at diagnosis (years)
67–70 23,498 15.2 5,437 15.0 3,661 11.1 5,339 14.9 9,061 18.2
71–75 44,578 28.8 9,936 27.4 7,503 22.7 10,631 29.7 16,508 33.2
76–80 41,887 27.1 9,630 26.6 8,545 25.9 10,090 28.2 13,622 27.4
>80 44,729 28.9 11,209 30.1 13,296 40.3 9,701 27.1 10,523 21.2
Mean and (SD) age 76.3 (6.7) 76.6 (6.5) 78.1 (6.8) 76.0 (6.0) 75.1 (7.0)
Gender
Male 83,272 53.8 NI NI 14,739 44.7 18,819 52.6 49,714 100
Female 71,420 46.2 36,212 100 18,266 55.3 16,942 47.4 NA NA
Race/ethnicity
White 131,000 84.7 31,923 88.2 28,162 85.3 30,824 86.2 40,091 80.6
Black 11,227 7.3 2,048 5.7 2,158 6.5 2,609 7.3 4,412 8.9
Hispanic 5,374 3.5 1,066 2.9 1,182 3.6 987 2.8 2,139 4.3
Other 7,091 4.6 1,175 3.2 1,503 4.6 1,341 3.8 3,072 6.2
Year of diagnosis
1999 21,578 14.0 5,300 14.6 4,542 13.8 4,527 12.7 7,209 14.5
2000 44,195 28.6 10,283 28.4 9,701 29.4 10,421 29.1 13,790 27.7
2001 44,927 29.0 10,517 29.0 9,486 28.7 10,613 29.7 14,311 28.8
2002 43,992 28.4 10,112 27.9 9,276 28.1 10,200 28.5 14,404 29.0
Stage at diagnosis
In situ 8,456 8.1 5,697 15.7 2,759 8.4 NI NI NI NI
I 34,001 32.4 16,493 45.6 8,635 26.2 8,873 24.8 NA NA
II 21,374 20.4 10,565 29.2 9,575 29.0 1,234 3.5 NA NA
III 20,737 19.8 1,852 5.1 7,195 21.8 11,690 32.7 NA NA
IV 20,410 19.4 1,605 4.4 4,841 14.7 13,964 39.1 NA NA
Localized 47,244 95.0 NA NA NA NA NA NA 47,244 95.0
Distant 2,470 5.0 NA NA NA NA NA NA 2,470 5.0
Percent in census tract with some college∗
<25% 53,892 34.8 11,975 33.1 12,016 36.4 12,690 35.5 17,211 34.6
≥25% 100,781 65.2 24,233 66.9 20,984 63.6 23,067 64.5 32,497 65.4
Percent in census tract living in poverty
<5% 48,053 31.1 11,773 32.5 9,935 30.1 9,928 27.8 16,417 33.0
5–7% 21,425 13.9 5,366 14.8 4,580 13.9 4,739 13.3 6,740 13.6
8–12% 34,511 22.3 8,226 22.7 7,538 22.8 8,049 22.5 10,698 21.5
>12% 48,929 31.6 10,428 28.8 10,511 31.9 12,689 35.5 15,301 30.8
Missing 1,774 1.2 419 1.2 441 1.3 356 1.0 558 1.1
Type of geographic area
Large metropolitan 86,555 56.0 20,678 57.1 18,383 55.7 19,759 55.3 27,735 55.8
Metropolitan 42,693 27.6 10,139 28.0 9,077 27.5 9,686 27.1 13,791 27.7
Urban 9,799 6.3 2,206 6.1 2,084 6.3 2,444 6.8 3,065 6.2
Less urban/rural 15,645 10.1 3,189 8.8 3,461 10.5 3,872 10.8 5,123 10.3
SD: standard deviation; NI: not included in the study; NA: not applicable; ∗19 patients had a missing value.
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Table 2: Measures of prior health care system contact.
Overall Type of cancer
Breast Colorectal Lung Prostate
𝑁 % 𝑛 % 𝑛 % 𝑛 % 𝑛 %
154,692 100 36,212 23.4 33,005 21.3 35,761 23.1 49,714 32.1
NCI comorbidity index
0 100,929 65.3 25,174 69.5 22,151 67.1 19,284 53.9 34,320 69.0
1 34,778 22.5 7,582 20.9 6,917 21.0 9,890 27.7 10,389 20.9
≥2 18,985 12.3 3,456 9.5 3,937 11.9 6,587 18.4 5,005 10.1
Preventive services
0 33,873 21.9 6,937 19.2 8,322 25.2 8,866 24.8 9,748 19.6
1 40,735 26.3 8,582 23.7 9,567 29.0 9,640 27.0 12,946 26.0
≥2 80,084 51.8 20,693 57.1 15,116 45.8 17,255 48.3 27,020 54.4
Types of physician visits
Primary care and medical specialist 87,436 56.5 21,857 60.4 17,591 53.3 19,573 54.7 28,415 57.2
Primary care, no medical specialist 22,462 14.5 7,285 20.1 6,577 19.9 6,490 18.2 6,686 13.5
Medical specialist, no primary care 27,038 17.5 3,839 10.6 4,738 14.4 5,060 14.2 8,825 17.8
Other specialist only 3,952 2.6 942 2.6 878 2.7 951 2.7 1,181 2.4
None 13,804 8.9 2,289 6.3 3,221 9.8 3,687 10.3 4,607 9.3
proportion is lower than the one obtained from the general
population sampled in NHANES [9], in which participants
underwent an oral glucose tolerance test and the results
were compared to self-reported history of diabetes to classify
patients as previously diagnosed or undiagnosed. In that
study, compared to the group with normal glucose tolerance,
those with undiagnosed diabetes were more likely to be
nonwhite race/ethnicity and to have less than a high school
education. In this regard, our findings were similar in this
cohort of elderly cancer patients, all of whom had at least two
years of health insurance prior to cancer diagnosis.
Furthermore, we found that the highest rates of undiag-
nosed diabetes were observed in those with limited health
system contact prior to cancer and in those with advanced-
stage cancer. Previous research shows that limited health
system contact is associated with advanced-stage cancer
at diagnosis [16–18]. However, the fact that limited health
system contact is associated with both advanced stage and
undiagnosed diabetes does not rule out other mechanisms,
for example, biological, linking undiagnosed diabetes directly
to cancer stage. In addition, in unadjusted models, and
several of the adjusted models, both higher levels of poverty
and lower levels of education were associated with a greater
likelihood of diabetes being diagnosed in the period around
cancer diagnosis. This suggests that socioeconomic factors
are contributors to undiagnosed diabetes. The fact that
models with all risk factors show some attenuation of the
socioeconomic factors suggests that interaction with the
healthcare system and socioeconomic status are confounded.
The association between undiagnosed diabetes and can-
cer prognosis is complex. Plausible mechanisms include
exacerbated biological effects [3–5] and the added burden on
the health care team of managing a previously undiagnosed
condition [2], which could impact treatment selection [12]
and response [7, 11]. Nevertheless, our findings indicate that
those already at the greatest risk of poor cancer outcomes due
to advanced stage also are most likely to bear any additional
adverse prognostic burden of undiagnosed diabetes.
Our study has several limitations. The approach to
identifying undiagnosed diabetes entailed first dividing an
observation period from 24 months before to 3 months after
cancer diagnosis into a look-back period and an incidence
period, then using a claims-based algorithm [24] to identify
diabetes in each period, and finally excluding those with
preexisting diabetes from the incidence risk set. The claims-
based algorithm we used has a sensitivity of 70% [24].
Also, in our study, the overall prevalence of diabetes during
the observation period (look-back and incidence periods
combined) was lower than that previously reported in the
literature based, for instance, on hospital medical records
review [13]. Consequently, it is likely that we have also
underestimated the incidence of undiagnosed diabetes.
Also, to preserve a large sample and include patients as
close to the minimum age for Medicare eligibility (65 years)
as possible, we established the beginning of the look-back
period at 24 months before cancer diagnosis, thereby making
the minimum age at cancer diagnosis 67 years in this cohort.
Many of these patients had a claims history beginning more
than 24 months before cancer. However, we elected not to
use these in identifying preexisting diabetes because this
may have indirectly biased the association between patient
age at cancer diagnosis and the incidence of undiagnosed
diabetes. Extending the look-back period farther back in
time could have resulted in detecting and excluding more
cases of preexisting diabetes and possibly also reducing
misclassification of preexisting diabetes as undiagnosed cases
during the incidence period, but that would have resulted in
smaller sample sizes and the exclusion of younger patients.
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Table 3: Incidence of undiagnosed diabetes during 6-month period around cancer diagnosis.
Overall Type of cancer
Breast Colorectal Lung Prostate
𝑁 % 𝑛 % 𝑛 % 𝑛 % 𝑛 %
2,678 1.7 370 1.0 904 2.7 983 2.7 421 0.8
Age at diagnosis (years)
67–70 391 1.66 45 0.83 102 2.79 160 3.00 84 0.93
71–75 753 1.69 94 0.95 218 2.91 318 2.99 123 0.75
76–80 696 1.66 98 1.02 221 2.59 277 2.75 100 0.73
>80 838 1.87 133 1.19 363 2.73 228 2.35 114 1.08
Gender
Male 1,421 1.71 NI NI 447 3.03 553 2.94 421 0.8
Female 1,257 1.76 370 1.02 457 2.50 430 2.54 NA NA
Race/ethnicity
White 2,091 1.60 289 0.91 705 2.50 779 2.53 318 0.79
Black 300 2.68 50 2.44 94 4.36 109 4.18 47 1.07
Hispanic 144 2.02 15 1.41 49 4.15 45 4.56 35 1.64
Other 143 2.02 16 1.36 56 3.73 50 3.73 21 0.68
Year of diagnosis
1999 365 1.7 57 1.08 105 2.31 136 3.00 67 0.93
2000 746 1.7 91 0.88 251 2.59 275 2.64 129 0.94
2001 795 1.8 117 1.11 284 2.99 280 2.64 114 0.80
2002 772 1.8 105 1.04 264 2.85 292 2.86 111 0.77
Stage at diagnosis
In situ 77 0.91 22 0.39 55 1.99 NI NI NI NI
I 669 1.24 110 0.67 215 2.94 200 2.25 NA NA
II 501 1.89 144 1.36 282 2.95 26 2.11 NA NA
III 602 2.60 38 2.05 227 3.15 314 2.69 NA NA
IV 690 2.88 56 3.49 125 2.58 443 3.17 NA NA
Localized NA NA NA NA NA NA NA NA 50 2.02
Distant NA NA NA NA NA NA NA NA 371 0.79
Percent in census tract with some college
<25% 1,087 2.02 151 1.26 374 3.11 397 3.13 165 0.96
≥25% 1,590 1.58 219 0.90 529 2.52 586 2.54 256 0.79
Percent in census tract living in poverty
<5% Not shown
5–7% 323 1.51 49 0.91 105 2.29 118 2.49 51 0.76
8–12% 606 1.76 81 0.98 204 2.71 220 2.73 101 0.94
>12% 1,073 2.19 157 1.51 355 3.38 394 3.11 167 1.09
Missing Not shown
Type of geographic area
Large metropolitan 1,513 1.75 204 0.99 512 2.79 566 2.86 231 0.83
Metropolitan 660 1.55 103 1.02 226 2.49 230 2.37 101 0.73
Urban 175 1.79 29 1.31 59 2.83 60 2.45 27 0.88
Less urban/rural 330 2.11 34 1.07 107 3.09 127 3.28 62 1.21
NI: not included in the study; NA: not applicable; not shown: one or more cells contained fewer than 11 observations.
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Table 4: Multivariate analyses of undiagnosed diabetes (all 3 measures of prior health system contact in each model).
Type of cancer
Breast Colorectal Lung Prostate
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
Age at diagnosis (years)
67–70 Reference
71–75 1.18 0.83 1.70 1.16 0.91 1.47 1.05 0.86 1.27 0.88 0.66 1.16
76–80 1.28 0.90 1.84 1.06 0.83 1.35 0.98 0.81 1.20 0.91 0.68 1.23
>80 1.28 0.91 1.81 1.15 0.91 1.45 0.86 0.70 1.06 1.37 1.03 1.82
Gender
Male Not applicable Reference Not applicable
Female Not applicable 0.86 0.75 0.99 0.95 0.83 1.08 Not applicable
Race/ethnicity
White Reference
Black 1.63 1.17 2.28 1.37 1.08 1.75 1.38 1.11 1.73 0.86 0.61 1.21
Hispanic 1.12 0.65 1.91 1.38 1.02 1.87 1.62 1.18 2.22 1.49 1.03 2.16
Other 1.39 0.83 2.33 1.48 1.11 1.96 1.43 1.06 1.92 0.80 0.50 1.26
Year of diagnosis
1999 Reference
2000 0.78 0.56 1.10 1.12 0.89 1.42 0.87 0.71 1.08 0.97 0.72 1.31
2001 0.98 0.71 1.35 1.30 1.03 1.63 0.88 0.72 1.09 0.84 0.62 1.14
2002 0.94 0.67 1.30 1.23 0.97 1.55 0.97 0.78 1.19 0.80 0.59 1.09
Percent in census tract with some college
<25% Reference
≥25% 0.77 0.61 0.95 0.89 0.77 1.02 0.86 0.75 0.99 0.89 0.72 1.10
Percent in census tract living in poverty
<5% Reference
5–7% 1.37 0.95 1.97 0.98 0.77 1.24 1.01 0.81 1.27 1.20 0.85 1.69
8–12% 1.40 1.01 1.94 1.11 0.91 1.35 1.08 0.89 1.31 1.44 1.08 1.92
>12% 1.68 1.24 2.28 1.20 0.99 1.44 1.06 0.86 1.32 1.41 1.06 1.87
Type of geographic area
Large metropolitan Reference
Metropolitan 1.04 0.81 1.34 0.90 0.77 1.07 0.82 0.70 0.96 0.82 0.64 1.04
Urban 1.27 0.84 1.92 1.03 0.77 1.36 0.83 0.63 1.10 0.92 0.69 1.40
less urban/rural 0.89 0.61 1.31 1.04 0.83 1.31 1.07 0.86 1.32 1.10 0.81 1.49
NCI comorbidity index
0 Reference
1 1.11 0.85 1.46 0.90 0.75 1.08 0.94 0.80 1.10 0.81 0.61 1.08
≥2 1.28 0.90 1.80 1.01 0.81 1.25 0.88 0.73 1.06 1.02 0.72 1.45
Preventive services
0 Reference
1 0.67 0.51 0.87 0.77 0.65 0.92 1.11 0.93 1.33 0.80 0.61 1.04
≥2 0.34 0.26 0.46 0.58 0.48 0.70 0.91 0.76 1.10 0.48 0.36 0.63
Types of physician visits
None Reference
Primary care and medical specialist 0.36 0.26 0.51 0.56 0.45 0.69 52 0.42 0.65 0.41 0.29 0.56
Primary care, no medical specialist 0.43 0.30 0.62 0.59 0.47 0.75 0.64 0.50 0.80 0.67 0.48 0.94
Medical specialist, no primary care 0.74 0.52 1.06 0.78 0.62 0.99 0.73 0.57 0.93 0.69 0.50 0.96
Other specialist only 1.06 0.66 1.71 0.87 0.60 1.27 0.93 0.65 1.33 0.89 0.53 1.49
OR: odds ratio; CI: confidence interval.
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Table 5: Multivariate analyses of undiagnosed diabetes (each measure of health system contact in a separate model)∗.
Type of cancer
Breast Colorectal Lung Prostate
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
NCI comorbidity index
0 Reference category
1 0.88 0.67 1.14 0.77 0.64 0.92 0.82 0.71 0.96 0.61 0.46 0.80
≥2 1.02 0.73 1.43 0.88 0.71 1.09 0.75 0.63 0.90 0.74 0.53 1.05
Preventive services
0 Reference category
1 0.52 0.41 0.67 0.65 0.56 0.77 0.89 0.76 1.05 0.59 0.47 0.75
≥2 0.24 0.18 0.30 0.46 0.39 0.54 0.68 0.58 0.79 0.31 0.24 0.39
Types of physician visits
None Reference category
Primary care and medical specialist 0.21 0.16 0.28 0.40 0.33 0.49 0.48 0.40 0.58 0.25 0.19 0.33
Primary care, no medical specialist 0.30 0.21 0.41 0.47 0.38 0.58 0.61 0.50 0.76 0.49 0.36 0.68
Medical specialist, no primary care 0.55 0.39 0.78 0.64 0.51 0.79 0.70 0.56 0.87 0.50 0.38 0.68
Other specialist only 0.83 0.52 1.33 0.75 0.52 1.09 0.91 0.64 1.30 0.73 0.44 1.22
∗Multivariate models also included age, gender (colorectal and lung cancer only), race/ethnicity, year of diagnosis, education, percent in census tract with some
college, percent in census tract living in poverty, and type of geographic area. OR: odds ratio; CI: confidence interval.
Furthermore, following precedent [9], we have described
diabetes first detected during the incidence period as “undi-
agnosed,” which implies that it was present but undetected
prior to that. However, simply by chance, it is likely that some
of these cases became diabetic during the incidence period.
Therefore, in this study, we may have underestimated the
magnitude and statistical significance of associations between
prior health system contact and undiagnosed diabetes.
This study was conducted prior to the implementation of
the Medicare Modernization Act (MMA), which introduced
new coverage for diabetes and other screening services in
2005 [33]. Introduction of these services is designed to
improve early detection of diabetes and other important con-
ditions. Therefore, rates of undiagnosed diabetes could have
changed due to the implementation of the MMA. In addition
to affecting the incidence of undiagnosed diabetes, theMMA
would impact services included in the preventive services
measure of prior health system contact. Since some of the
new services impact diabetes, it is possible that associations
between level of preventive services use and undiagnosed
diabeteswould become stronger as a result but that the overall
incidence of undiagnosed diabetes would have declined
through improved coverage of preventive services.
Limitations notwithstanding, our findings indicate that
undiagnosed diabetes is relatively common in selected sub-
groups of cancer patients, such as those with limited prior
health system contact and advanced cancer stage, and that
poverty and lower educational attainment may contribute
directly, as well as through limited interaction with the health
system. Also, those already at the greatest risk of poor cancer
outcomes due to advanced stage also are most likely to bear
any additional adverse prognostic burden of undiagnosed
diabetes. Possible explanations for the association between
undiagnosed diabetes and advanced stage include biological
mechanisms and/or shared risk factors. As the incidence of
diabetes continues to rise, understanding the relationship
between undiagnosed diabetes and cancer outcomes may
help inform treatment decisions in the management of these
patients.
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Legend: this figure presents the unadjusted incidence (%) of previously undetected diabetes, by cancer type and measure of prior health system contact.
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OS: specialist other than medical
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Figure 1: Incidence of undiagnosed diabetes and measure of prior health system contact.
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